Luvometinib
Phase 3Small molecule
Luvometinib is one of 88 small molecule programs targeting Glioma. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
394 competitors in Glioma
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Bicnu
MMelissa K Accordino
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Velban
EEastern Cooperative Oncology Group
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Modeyso
CChimerix
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Langerhans Cell Histiocytosis1 trial
Glioma1 trial
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
Not yet recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 3·NCT07004075·102 enrolled
Neurofibromatosis Type 11 trial
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Not yet recruiting·SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1/2·NCT07024394·65 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Luvometinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details